Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting

World News: . []

WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro atrial fibrillation clinical data from the GENETIC-AF Phase 2B trial have been selected for presentation at the Heart Failure Society of America (HFSA) being held September 13-16 in Philadelphia.  William T. Abraham, MD, FACP, FACC, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, will present the data.

“Bucindolol response appears to be greater in heart failure patients with less severe left ventricular dysfunction, a patient population with few therapeutic options for AF prevention or heart failure,” commented Dr. Abraham, “These data provide additional support for pharmacogenetic guided therapy with bucindolol for the prevention of atrial fibrillation in patients with heart failure We look forward to confirming these important findings in the upcoming Phase 3 PRECISION‑AF trial.”


More news and information about ARCA biopharma, Inc.

Published By:

Globe Newswire: 13:30 GMT Wednesday 11th September 2019

Published: .

Search for other references to "arca" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us